Literature DB >> 25160635

Molecular pathology - the value of an integrative approach.

Manuel Salto-Tellez1, Jacqueline A James2, Peter W Hamilton3.   

Abstract

Molecular Pathology (MP) is at the heart of modern diagnostics and translational research, but the controversy on how MP is best developed has not abated. The lack of a proper model or trained pathologists to support the diagnostic and research missions makes MP a rare commodity overall. Here we analyse the scientific and technology areas, in research and diagnostics, which are encompassed by MP of solid tumours; we highlight the broad overlap of technologies and analytical capabilities in tissue research and diagnostics; and we describe an integrated model that rationalizes technical know-how and pathology talent for both. The model is based on a single, accredited laboratory providing a single standard of high-quality for biomarker discovery, biomarker validation and molecular diagnostics.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Molecular diagnostics; Molecular pathology; Translational research

Mesh：

Substances：

Year:  2014        PMID： 25160635      PMCID： PMC5528577          DOI： 10.1016/j.molonc.2014.07.021

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  18 in total

1.  Molecular pathology in contemporary diagnostic pathology laboratory: an opinion for the active role of surgical pathologists.

Authors:  Gregory Y Lauwers; Stephen Black-Schaffer; Manuel Salto-Tellez
Journal:  Am J Surg Pathol       Date:  2010-01       Impact factor: 6.394

2.  Evolving concepts of quality in laboratory practice. A historical overview of quality assurance in clinical laboratories.

Authors:  D B Dorsey
Journal:  Arch Pathol Lab Med       Date:  1989-12       Impact factor: 5.534

3.  Models of biobanking and tissue preservation: RNA quality in archival samples in pathology laboratories and "in vivo biobanking" by tumor xenografts in nude mice-two models of quality assurance in pathology.

Authors:  Giorgio Stanta; Serena Bonin; Isidro Machado; Antonio Llombart-Bosch
Journal:  Biopreserv Biobank       Date:  2011-06       Impact factor: 2.300

Review 4.  Implementing personalized cancer genomics in clinical trials.

Authors:  Richard Simon; Sameek Roychowdhury
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 5.  From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience.

Authors:  Thomas R Muley; Felix Jf Herth; Philipp A Schnabel; Hendrik Dienemann; Michael Meister
Journal:  Transl Lung Cancer Res       Date:  2012-06

Review 6.  Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.

Authors:  M Dietel; K Jöhrens; Mv Laffert; M Hummel; H Bläker; B M Müller; A Lehmann; C Denkert; F L Heppner; A Koch; C Sers; I Anagnostopoulos
Journal:  Cancer Gene Ther       Date:  2013-03-15       Impact factor: 5.987

7.  The history of pathology informatics: A global perspective.

Authors:  Seung Park; Anil V Parwani; Raymond D Aller; Lech Banach; Michael J Becich; Stephan Borkenfeld; Alexis B Carter; Bruce A Friedman; Marcial Garcia Rojo; Andrew Georgiou; Gian Kayser; Klaus Kayser; Michael Legg; Christopher Naugler; Takashi Sawai; Hal Weiner; Dennis Winsten; Liron Pantanowitz
Journal:  J Pathol Inform       Date:  2013-05-30

Review 8.  Shifting emphasis from pharmacogenomics to theragnostics.

Authors:  Vural Ozdemir; Bryn Williams-Jones; Stephen J Glatt; Ming T Tsuang; James B Lohr; Christopher Reist
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

9.  Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.

Authors:  Clare M McCourt; Darragh G McArt; Ken Mills; Mark A Catherwood; Perry Maxwell; David J Waugh; Peter Hamilton; Joe M O'Sullivan; Manuel Salto-Tellez
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

10.  Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.

Authors:  Yalai Bai; Huan Cheng; Jennifer Bordeaux; Veronique Neumeister; Sudha Kumar; David L Rimm; David F Stern
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240
View more
  12 in total

1.  PICan: An integromics framework for dynamic cancer biomarker discovery.

Authors:  Darragh G McArt; Jaine K Blayney; David P Boyle; Gareth W Irwin; Michael Moran; Ryan A Hutchinson; Peter Bankhead; Declan Kieran; Yinhai Wang; Philip D Dunne; Richard D Kennedy; Paul B Mullan; D Paul Harkin; Mark A Catherwood; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton
Journal:  Mol Oncol       Date:  2015-03-04       Impact factor: 6.603

Review 2.  The ins and outs of molecular pathology reporting.

Authors:  Véronique Tack; Kelly Dufraing; Zandra C Deans; Han J van Krieken; Elisabeth M C Dequeker
Journal:  Virchows Arch       Date:  2017-03-26       Impact factor: 4.064

3.  High mobility group box-1 and its clinical value in breast cancer.

Authors:  Shanping Sun; Wei Zhang; Zhaoqing Cui; Qi Chen; Panpan Xie; Changxin Zhou; Baoguo Liu; Xiangeng Peng; Yang Zhang
Journal:  Onco Targets Ther       Date:  2015-02-12       Impact factor: 4.147

4.  Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.

Authors:  Mark Lawler; Anna Gavin; Manuel Salto-Tellez; Richard D Kennedy; Sandra Van Schaeybroeck; Richard H Wilson; Denis Paul Harkin; Margaret Grayson; Ruth E Boyd; Peter W Hamilton; Darragh G McArt; Jacqueline James; Tracy Robson; Robert D Ladner; Kevin M Prise; Joe M O'Sullivan; Timothy Harrison; Liam Murray; Patrick G Johnston; David J Waugh
Journal:  Cancer       Date:  2015-12-22       Impact factor: 6.860

5.  Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.

Authors:  Philip D Dunne; Paul G O'Reilly; Helen G Coleman; Ronan T Gray; Daniel B Longley; Patrick G Johnston; Manuel Salto-Tellez; Mark Lawler; Darragh G McArt
Journal:  Oncotarget       Date:  2016-06-14

Review 6.  Tissue-based next generation sequencing: application in a universal healthcare system.

Authors:  Seán O Hynes; Brendan Pang; Jacqueline A James; Perry Maxwell; Manuel Salto-Tellez
Journal:  Br J Cancer       Date:  2017-01-19       Impact factor: 7.640

Review 7.  The Role of ATRX in Glioma Biology.

Authors:  Pravanya Nandakumar; Alireza Mansouri; Sunit Das
Journal:  Front Oncol       Date:  2017-09-29       Impact factor: 6.244

8.  Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned.

Authors:  Gerald Li; Peter Bankhead; Philip D Dunne; Paul G O'Reilly; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton; Darragh G McArt
Journal:  Brief Bioinform       Date:  2017-07-01       Impact factor: 11.622

Review 9.  Time for change: a new training programme for morpho-molecular pathologists?

Authors:  Caroline A Young; Hayley T Morris; David A Moore; Karin A Oien; Jessica L Lee; J Louise Jones; Manuel Salto-Tellez
Journal:  J Clin Pathol       Date:  2017-11-07       Impact factor: 3.411

Review 10.  NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine.

Authors:  Federica Zito Marino; Francesca Pagliuca; Andrea Ronchi; Immacolata Cozzolino; Marco Montella; Massimiliano Berretta; Maria Elena Errico; Vittoria Donofrio; Roberto Bianco; Renato Franco
Journal:  Int J Mol Sci       Date:  2020-05-25       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.